CDRH Device Quality Update March 17, 2015
|
|
|
- Karin Griffin
- 6 years ago
- Views:
Transcription
1 CDRH Device Quality Update March 17, 2015 William C. MacFarland FDA/CDRH/OC/Division of Manufacturing and Quality 1
2 Agenda Themes for 2015 FDA Commissioner s Program Alignment FDA s Case for Quality 2015 Update Questions and Answers FDA News Quality 2 Con
3 Themes for 2015 Three familiar themes for device quality continue this year The device industry is not getting any simpler Money/budget for regulatory changes continue to be limited Expectations for regulatory change continue to be high FDA News Quality Congress - CDRH Update 3
4 PROGRAM ALIGNMENT FDA News Quality Congress - CDRH Update 4
5 Why: Program Alignment Increased complexity in FDA s mandate Impact of globalization on the supply chain Trend towards innovation What A plan to transition to a commodity-based program integrated with each of the product centers. 1 1: FDA News Quality Congress - CDRH Update 5
6 Program Alignment FDA News Quality Congress - CDRH Update 6
7 Program Alignment Regarding the timeline: Some foundational tasks are due before 10/2015 Longer term tasks are due in the next two fiscal years. Even in this early stage, CDRH and ORA talking about the benefits of aligning along product lines FDA News Quality Congress - CDRH Update 7
8 FDA S CASE FOR QUALITY UPDATE FDA News Quality Congress - CDRH Update 8
9 Current approach reinforces compliance not necessarily quality 1 Case for Quality 2 activities Projects that encourage operating above the regulatory baseline A forum for engaging on the device quality arena 1: 2: FDA News Quality 9 Con
10 Ongoing activities Stakeholder Forum Critical to Quality (CtQ) Implantable Devices/Battery Pilot DMQ CtQ Info Documents PMA CtQ Confirmation Pilot Library of Quality Practices Data Transparency Quality Measures FDA News Quality Congress - CDRH Update 10
11 Stakeholder Forum MDIC will convene this forum 1 Researching use of Quality Maturity Models Regular meetings to discuss: Areas for improving quality Chartering new approaches Updates on projects Some meetings targeted, some broad in scope 1: FDA News Quality Congress - CDRH Update 11
12 Critical to Quality (CtQ) Started as an inspection pilot CtQs generated via: Internal CDRH and ORA experts Technical stakeholder input CtQs written into inspectional guidance Shared with investigators Shared with firms being inspected 4 inspections completed FDA News Quality Congress - CDRH Update 12
13 Critical to Quality (CtQ) DMQ 2014 efforts PMA CtQ Info. Doc. Division Pilot 1 Tech. Stakeholder CtQ Info. Doc. RBWP CtQ Info. Doc. ASD Branch 4 1 CD Branch 2 POND Branch 1 1 REGO Branch 1 Total CtQ Information Documents: FDA CtQ Pilot: 1 DMQ division: 12 Total: 13 FDA News Quality Congress - CDRH Update 13
14 Critical to Quality (CtQ) current format Key characteristic Impact of failure Sphericity and surface finish of the endplates are two key characteristics, because nonconformity of either one of these key characteristics can lead to excessive wear, which can ultimately lead to pain, metal debris inside the end-user s body, and need for revision surgery. Control A. Sphericity is primarily an output of the CNC Turning, CNC Milling, and Deburring processes and verified through the Dimensional Inspection Process [21 CFR ] [QSIT P&PC Objective #2] Reference to 820 Reference to QSIT FDA News Quality Congress - CDRH Update 14
15 (new) PMA CtQ Confirmation Pilot For those PMA manufacturing sections with no deficiencies in the original submission Applicant inspected within the last five years For applicants willing to participate Applicant submits CtQs. FDA reviews. Preapproval confirmation of controls. Postapproval QSIT FDA News Quality Congress - CDRH Update 15
16 (new) FDA Library of Quality Practices A resource that promotes building the knowledge-base on device quality. Working with other organizations but also making our own internal training material more readily available Look for more on this concept as we develop it throughout FDA News Quality Congress - CDRH Update 16
17 Quality Measures Interested in indicators of product quality Identifying measures tied to best practices Preproduction, production and postproduction Workgroup comprised of industry and agency personnel Expecting compilation of measures by mid-year and discussion at MDIC. FDA News Quality Congress - CDRH Update 17
18 Data Transparency Stakeholder needs assessment Informed Inspections Application Programming Interface (API) 3 rd party data analysis FDA News Quality Congress - CDRH Update 18
19 Look for further opportunities to interact on device quality with FDA In the meantime, consider asking: What does the term quality mean to me? How do we use this term at our company? Are our company s current high-priority projects focused on quality system execution? Are they focused on ensuring overall device quality? FDA News Quality 19 Con
20 Contact Information Bill MacFarland Director, Division of Manufacturing and Quality FDA, Center for Devices and Radiological Health Office of Compliance Division of Manufacturing and Quality Building WHITE OAK #66, Rm New Hampshire Avenue Silver Spring, MD Tel: FDA News Quality Congress - CDRH Update 20
2015 Annual FDA Medical Device Quality System Data. Inspections, FDA Form 483 Observations, and Warning Letter Citations
2015 Annual FDA Medical Device Quality System Data Inspections, FDA Form 483 Observations, and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and
LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S.
LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S. Food and Drug Administration 1 Office of the Commissioner
FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update
FDA s Office of Regulatory Affairs: Violation Trends & Medical Device Update Ginger M. Sykes Supervisory Consumer Safety Officer Salt Lake City Resident Post Office of Regulatory Affairs U.S. Food and
Focus on Medical Device: A conversation about Case for Quality. September 22, 2017
Focus on Medical Device: A conversation about Case for Quality September 22, 2017 Agenda Welcome and Introductions Why create a Voluntary Program? What is the Voluntary Program? Q&A 2017 Grant Thornton
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1
Center for Drug Evaluation and Research - Compliance Central with FDA Center Compliance Directors: Part 1 Donald D. Ashley, JD 2017 FDLI Enforcement, Litigation, and Compliance Conference: For the Drug,
Guidance for Industry
Guidance for Industry Self-Identification of Generic Drug Facilities, Sites, and Organizations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
Investigator Roles and Responsibilities in Clinical Device Trials
Investigator Roles and Responsibilities in Clinical Device Trials A Total Product Lifecycle Approach to Medical Device Development: Responsibilities and Opportunities The Stanford Center for Clinical and
MDUFA Performance Goals and Procedures Process Improvements Pre-Submissions Submission Acceptance Criteria Interactive Review
Page 1 MDUFA Performance Goals and Procedures... 3 I. Process Improvements... 3 A. Pre-Submissions... 3 B. Submission Acceptance Criteria... 4 C. Interactive Review... 5 D. Guidance Document Development...
Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission
This document is scheduled to be published in the Federal Register on 06/07/2018 and available online at https://federalregister.gov/d/2018-12223, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Packaging, Storage, and Disposal Options to Enhance Opioid Safety--Exploring the Path
This document is scheduled to be published in the Federal Register on 10/31/2017 and available online at https://federalregister.gov/d/2017-23535, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
:,-, WARNING LETTER. Mr. Jean Claude Mas Chief Executive Officer Poly Implants Protheses, Sa 337 Avenue De Bruxelles La Seyne, Sur Mer France
+., %- *: $1.,X,, *,+,,r + $, DEPARTMENT +, %, >,,, :,-, OF HEALTH & HUMAN SERVICES Public Health Service VIA FEDERAL EXPRESS ~ 22moo WARNING LETTER Mr. Jean Claude Mas Chief Executive Officer Poly Implants
I. Preamble: II. Parties:
I. Preamble: MEMORANDUM OF UNDERSTANDING BETWEEN THE FEDERAL COMMUNICATIONS COMMISSION AND THE FOOD AND DRUG ADMINISTRATION CENTER FOR DEVICES AND RADIOLOGICAL HEALTH The Food and Drug Administration (FDA)
Food Safety Modernization Act (FSMA)
Food Safety Modernization Act (FSMA) FDA FSMA Timeline July 29, 2009 House version passed Votes 283-142 Nov. 30, 2010 Senate version passed Votes 73-25 Dec. 19, 2010 Senate revised version passed Unanimous
1. Review the scenario, resource list, and scenario map in your handouts.
Unit 2. ICS Fundamentals INSTRUCTOR NOTES UNIT 2: PET FOOD RECALL SCENARIO Objective: To review the key concepts of ICS. Instructions: Ask the participants to work in teams to complete the following activity:
Solutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
Solutions for GCP Compliance Challenges
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug
This document is scheduled to be published in the Federal Register on 03/14/2016 and available online at http://federalregister.gov/a/2016-05573, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements
Guidance for Industry and FDA Staff Interactive Review for Medical Device Submissions: 510(k)s, Original PMAs, PMA Supplements, Original BLAs, and BLA Supplements Document Issued on: February 28, 2008
Training Update: Preventive Controls Regulator Training
Training Update: Preventive Controls Regulator Training Patricia L. Alcock Director, Office of Training, Education and Development Food and Drug Administration 1/30/2018 9:00 AM Today s Agenda - Preventive
Medical Device Recall Report FY FY 2012
Medical Device Recall Report FY 2003- FY 2012 Ann Ferriter Division of Analysis and Program Operations Office of Compliance Center for Devices and Radiological Health Questions Why did FDA draft the Medical
Pre-Submissions and Meetings with FDA Staff
Pre-Submissions and Meetings with FDA Staff Soma Kalb, PhD Acting Director, IDE Program Office of Device Evaluation Elizabeth Hillebrenner, MSE Policy Analyst Office of In Vitro Diagnostics & Radiological
Purnendu C. Vasavada, Ph.D. Coordinator, FSPCA
The Food Safety Preventive Control Alliance (FSPCA): A Public-Private Partnership to Assist Food Industry Compliance with the Preventive Controls regulations Purnendu C. Vasavada, Ph.D. Coordinator, FSPCA
ENVIRONMENT CANADA S ECONOMIC AND ENVIRONMENTAL POLICY RESEARCH NETWORK CALL FOR PROPOSALS
ENVIRONMENT CANADA S ECONOMIC AND ENVIRONMENTAL POLICY RESEARCH NETWORK CONTEXT CALL FOR PROPOSALS As part of its commitment to strengthen academic engagement, within the areas of economics and policy
Review of Existing Center for Drug Evaluation and Research Regulatory and Information
This document is scheduled to be published in the Federal Register on 09/08/2017 and available online at https://federalregister.gov/d/2017-19033, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
FDA Outlook Seth A. Mailhot, Partner Lead, FDA Regulatory Practice
FDA Outlook 2017 Seth A. Mailhot, Partner Lead, FDA Regulatory Practice January,25, 2017 Overview Gaming the Elections Influence on FDA in 2017 Potential Congressional Activity PDUFA VI and MDUFA IV Restructuring
510(k) Clinical Data Requirements: Current Status and Considerations for Clinical Studies
510(k) Clinical Data Requirements: Current Status and Considerations for Clinical Studies Sandra Maddock, RN, BSN, CCRA IMARC Research, Inc. Introduction In an effort to promote innovation while protecting
PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS
PLAN OF ACTION FOR IMPLEMENTATION OF 510(K) AND SCIENCE RECOMMENDATIONS In August 2010, the Food and Drug Administration s Center for Devices and Radiological Health (CDRH or the Center) released for public
Intellectual Disability Waiver Transition Plan Regarding Compliance with the HCBS Final Rule Elements July 30, 2014
Intellectual Disability Waiver Transition Plan Regarding Compliance with the HCBS Final Rule Elements July 30, 2014 Assessment of Waiver and Service Definitions Virginia is currently in the process of
Document issued on: July 8, 2010
Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and Food and Drug Administration Staff Humanitarian Device Exemption (HDE) Regulation: Questions and Answers Document
Laboratory Chemical Hygiene Plan Research Lab
Laboratory Chemical Hygiene Plan Research Lab A chemical hygiene plan is a written program developed to establish procedures, protective equipment requirements and standard work practices that promote
FDA SEATTLE DISTRICT REGULATORY UPDATE
FDA SEATTLE DISTRICT REGULATORY UPDATE SEAFOOD PRODUCTS ASSOCIATION PROCESSORS WORKSHOP SEATTLE, WASHINGTON MARCH 10, 2015 MIRIAM R. BURBACH SEATTLE DISTRICT DIRECTOR 1 FDA SEATTLE DISTRICT REGULATORY
DOD Anti-Counterfeit Rule Requires Immediate Action --By Craig Holman, Evelina Norwinski and Dana Peterson, Arnold & Porter LLP
Published by Government Contracts Law360 on May 19, 2014. Also ran in Aerospace & Defense Law360 and Public Policy Law360. DOD Anti-Counterfeit Rule Requires Immediate Action --By Craig Holman, Evelina
Inspections, Compliance, Enforcement, and Criminal Investigations
1 of 5 2/11/2014 11:24 AM Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Baxter
Drug and Medical Device Registration FAQ
Drug and Medical Device Registration FAQ Contents Types of Submissions... 3 When is it appropriate to submit a new application form F-2?... 3 Do I need to submit a new application for a new or changed
INFECTION CONTROL SURVEYOR WORKSHEET
Attachment 2 Exhibit 351 INFECTION CONTROL SURVEYOR WORKSHEET Instructions: The following is a list of items that must be assessed during the on-site survey, in order to determine compliance with the infection
FDA Vision for Innovative Surveillance of Orthopedic Implants
FDA Vision for Innovative Surveillance of Orthopedic Implants Danica Marinac-Dabic, MD, PhD Director, CDRH Division of Epidemiology Head, FDA ICOR Initiative Total and Resurfacing Hip Systems: Post-Approval
CDRH Standards Program
Standards Scott Colburn Deputy Director Standards Management Staff FDA/CDRH/OSEL 1 CDRH Standards Program Standards needs/priorities New projects Travel / Travel priorities Standards review Standards ballot
Workplace Violence Prevention indicator in hospital Quality Improvement Plans (QIPs)
Workplace Violence Prevention indicator in hospital Quality Improvement Plans (QIPs) S U D H A K U T T Y, HQO, DIRECTOR, QUALITY IMPROVEMENT STRATEGIES & ADOPTION D A N Y A L MA R T I N, H Q O, MA N A
. s%rwcu ~,+ *+ % %vd3a 7 Food and Drug Administration. Center for Devices and
* %. s%rwcu ~,+ *+ Jf ~ DEPARTMENT OF HEAITH & HUMAN SERVICIB Public Health Setvice z 2 4/5924 % % %vd3a 7 Food and Drug Administration. Center for Devices and Radiological 2098 Gaither Road Via Federal
Guidance for Industry and Food and Drug Administration Staff
Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff Guidance for Industry and Food and Drug Administration Staff Document
TABLE OF CONTENTS. Request for Proposals (RBFF-18-C-387) STRATEGIC PLANNING FACILITATOR I. Request for Proposals. II.
TABLE OF CONTENTS Request for Proposals (RBFF-18-C-387) STRATEGIC PLANNING FACILITATOR - 2018 I. Request for Proposals II. Solicitation III. Background IV. Project Need V. Project Scope VI. Contractor
April 17, Edition of the Joint Commission International Accreditation. SUBJECT: MITA Feedback on the 5 th Standards for Hospitals
1300 North 17 th Street Suite 1752 Arlington, Virginia 22209 Tel: 703.841.3200 Fax: 703.841.3392 www.medicalimaging.org April 17, 2013 Paul vanostenberg, DDS, MS Vice President Accreditation and Standards
Specific Comments on Proposed Amendments
June 8, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 RE: Docket No. FDA 2002-N-0323 Proposed Rulemaking: Amendments to Registration
Changes to QSR. The table below provides a history of changes to FDA s Quality System Regulation (QSR)
Changes to QSR The table below provides a history of changes to FDA s Quality System Regulation (QSR) The citation is to the Federal R: the first number is the volume, FR indicates the Federal Register,
DEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter,
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Ronald Bukowski, M.D. 28099 Gates Mills
Postmarketing Drug Safety and Inspection Readiness
Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration
FDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7
FDA's OMB supporting document for QSr recordkeeping, 7/20/01, page 1 of 7 DISCLAIMER: This document was prepared by editing the converted PDF file supporting FDA's request to OMB for continuation of record
The Mammography Quality Standards Act Final Regulations Motion of Tube-Image Receptor Assembly
Compliance Guidance The Mammography Quality Standards Act Final Regulations Motion of Tube-Image Receptor Assembly Document issued on March 23, 1999 U.S. Department Of Health And Human Services Food and
Agency Information Collection Activities; Proposed Collection; Comment Request; Survey
This document is scheduled to be published in the Federal Register on 07/02/2018 and available online at https://federalregister.gov/d/2018-14158, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Federal Funding Opportunity Page 1 of 13. Fiscal Year 2019 National Sea Grant College Program Dean John A. Knauss Marine Policy Fellowship
Federal Funding Opportunity Page 1 of 13 Fiscal Year 2019 National Sea Grant College Program Dean John A. Knauss Marine Policy Fellowship TABLE OF CONTENTS I. Funding Opportunity Description 3 A. Program
TESTIMONY OF THOMAS HAMILTON DIRECTOR SURVEY & CERTIFICATION GROUP CENTER FOR MEDICAID AND STATE OPERATIONS CENTERS FOR MEDICARE & MEDICAID SERVICES
TESTIMONY OF THOMAS HAMILTON DIRECTOR SURVEY & CERTIFICATION GROUP CENTER FOR MEDICAID AND STATE OPERATIONS CENTERS FOR MEDICARE & MEDICAID SERVICES ON CLIA AND GENETIC TESTING BEFORE THE SENATE SPECIAL
RE: Docket No. FDA 2015 N FDA Food Safety Modernization Act: Focus on Implementation Strategy for Prevention-Oriented Food Safety Standards
May 26, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 RE: Docket No. FDA 2015 N 0797 - FDA Food Safety Modernization Act: Focus
Pediatric Medical Devices: The FDA Postmarket Perspective
Pediatric Medical Devices: The FDA Postmarket Perspective Thomas P. Gross, MD, MPH Deputy Office Director Office of Surveillance and Biometrics Center for Devices and Radiological Health Pediatric Safety
FDA Guidance Hot Topics: Pre-Submission Guidance Review AMDM Focus Meeting October 25, Elizabeth Hillebrenner, MSE OIR/CDRH/FDA
FDA Guidance Hot Topics: Pre-Submission Guidance Review AMDM Focus Meeting October 25, 2013 Elizabeth Hillebrenner, MSE OIR/CDRH/FDA Updates to Guidance: Draft Final Broaden scope to address all types
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
DEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice WARNING LETTER
DEPARTMENT OF HEALTH & Hl'NIAfV SERVICES Public Hcaffh Scn-ice Food and Drug Administration 9200 CCorporate Bl%d. RockOlc MD 20550 WARNING LETTER VIA FEDERAL EXPRESS MP 4 2007 William D. Tobler, MD Mayfield
Case: 1:10-cv Document #: 74-1 Filed: 04/15/11 Page 1 of 7 PageID #:2403 EXHIBIT A
Case: 1:10-cv-06016 Document #: 74-1 Filed: 04/15/11 Page 1 of 7 PageID #:2403 EXHIBIT A Case: 1:10-cv-06016 Document #: 74-1 Filed: 04/15/11 Page 2 of 7 PageID #:2404 UNITED STATES DISTRICT COURT NORTHERN
Concept Paper for ANN VISTA Project for FY 2012 Submitted
Executive Summary Concept Paper for ANN VISTA Project for FY 2012 Submitted 12-11-11 1. Provide a brief description of the proposed project, including the project goal(s) as well as an overview of the
Delayed Federal Grant Closeout: Issues and Impact
Delayed Federal Grant Closeout: Issues and Impact Natalie Keegan Analyst in American Federalism and Emergency Management Policy September 12, 2014 Congressional Research Service 7-5700 www.crs.gov R43726
Pay for Performance and Health Information Technology: Overview of HIT Pay for Performance Initiatives
Pay for Performance and Health Information Technology: Overview of HIT Pay for Performance Initiatives National Pay for Performance Summit Janet M. Marchibroda Chief Executive Officer ehealth Initiative
Quality Risk Management ICH Q9
Quality Risk Management ICH Q9 Executive summary for competent authorities and industry Disclaimer: This presentation includes the author s views on quality risk management theory and practice. The presentation
WARNING LETTER CERTIFIED MAIL -~ Q December 14, 2005
-~ Q DEPARTMENT Or HEALTI-I A\D HUMAN SERVICES Public Health Service Food and Drug Administration Central Region Telephone (973) 526-6006 New Jersey District Waterview Corporate Center 10 Waterview Blvd.,
Topic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015
Topic: CAP s Legislative Proposal for Laboratory-Developed Tests (LDT) Date: September 14, 2015 1. What are the CAP s views on the regulatory oversight of laboratory-developed tests (LDTs)? 2. How are
Medical Devices and Device-Led Combination Products; Voluntary Malfunction Summary
This document is scheduled to be published in the Federal Register on 08/17/2018 and available online at https://federalregister.gov/d/2018-17770, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
Care Redesign: An Essential Feature of Bundled Payment
Issue Brief No. 11 September 2013 Care Redesign: An Essential Feature of Bundled Payment Jett Stansbury Director, New Payment Strategies, Integrated Healthcare Association Gabrielle White, RN, CASC Executive
Real-World Evidence: A CDRH Perspective
Real-World Evidence: A CDRH Perspective Karen Ulisney, MSN, CRNP Policy Analyst, Clinical Trials Program Office of Device Evaluation CDRH, FDA Case for Quality Forum July 20, 2017 Patients are at the Heart
TOWN OF GREENWICH Annual Department Operational Plan (FY )
TOWN OF GREENWICH Annual Department Operational Plan (FY 2012 2013) 1. Department: Inland Wetlands and Watercourses Agency 2. Divisions: N/A 3. Department Mission Statement: The Inland Wetlands and Watercourses
FDA Perspective on the Pre- Submission Program: Updates from MDUFA IV
FDA Perspective on the Pre- Submission Program: Updates from MDUFA IV Maureen Dreher, PhD Policy Analyst Clinical Trials Program/ Office of Device Evaluation/ CDRH Agenda Pre-Submission Program background
Complaint Handling and Medical Device Reporting (MDRs)
Complaint Handling and Medical Device Reporting (MDRs) FDA Small Business Regulatory Education for Industry (REdI) Bethesda, MD September 26, 2013 Andrew Xiao Consumer Safety Officer, Postmarket and Consumer
FDA. Office of Criminal Investigations
FDA Office of Criminal Investigations Established in March 1992 by the Commissioner, with the urging of Congress, in response to concerns of increased criminal violations of the Act 1 OCI Mission Statement
ARIZONA ASSOCIATION OF CONSERVATION DISTRICTS STRATEGIC PLAN P age 75 Years of Locally Led Conservation
ARIZONA ASSOCIATION OF CONSERVATION DISTRICTS STRATEGIC PLAN 2017-2020 1 P age 75 Years of Locally Led Conservation 2 P a g e 75 Years of Locally Led Conservation OUR MISSION To support Conservation Districts
Pilot Project Program Under the Drug Supply Chain Security Act; Request for Comments
This document is scheduled to be published in the Federal Register on 07/20/2017 and available online at https://federalregister.gov/d/2017-15203, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
Received an RTA Deficiency List or AI Letter? Now What?
Received an RTA Deficiency List or AI Letter? Now What? Dealing with Unexpected Issues/Questions during the Submission Review Process Navigating Submission Challenges to reduce time & risk September 26,
FDA Office of Acquisitions and Grants Services Overview
FDA Office of Acquisitions and Grants Services Overview Presentation to the Association of Food and Drug Officials (AFDO) February 3, 2016 1 Contents Who We Are/What We Do Contract vs. Grant Grant Flexibilities
BIMO Program Update an operational perspective
BIMO Program Update an operational perspective Clinical Trials Summit San Juan, Puerto Rico May 9, 2018 Anne E. Johnson Program Division Director FDA/ORA/OBIMO Division I (East) 1 Objectives Program Alignment
Pediatric Medical Device Development and Safety. Jacqueline N. Francis, MD, MPH Medical Officer, PSRB, ODE, CDRH, FDA
Pediatric Medical Device Development and Safety Jacqueline N. Francis, MD, MPH Medical Officer, PSRB, ODE, CDRH, FDA This presentation represents the professional opinion of the speaker and is not an official
USAID Civic Initiatives Support Program. Civic Initiatives Support Fund Annual Program Statement 2014
USAID Civic Initiatives Support Program Civic Initiatives Support Fund Annual Program Statement 2014 FREQUENTLY ASKED QUESTIONS (FAQs) as of August 26, 2014 This document provides information on a variety
New England District Update FDA s Office of Regulatory Affairs Aligns for the Future
New England District Update FDA s Office of Regulatory Affairs Aligns for the Future MassMedic December 12, 2017 Waltham, MA Joseph S. Matrisciano Jr, JD, PE Director, New England District Director, Office
The Mammography Quality Standards Act Final Regulations Quality Assurance Documentation
Compliance Guidance The Mammography Quality Standards Act Final Regulations Quality Assurance Documentation Document issued on December 7, 1999 U.S. Department Of Health And Human Services Food and Drug
Clinical Research Seminar
Clinical Research Seminar HOW TO DEVELOP A CORRECTIVE AND PREVENTIVE ACTION PLAN (THAT EVEN THE IRB AND FDA WILL LOVE) April 11, 2018 Fiona Rice, MPH Human Research Quality Manager fionar@bu.edu Mary-Tara
Innovation in Medical Evidence Development and Surveillance Program (IMEDS) Gregory Daniel, PhD, MPH January 31, 2013
Innovation in Medical Evidence Development and Surveillance Program (IMEDS) Gregory Daniel, PhD, MPH January 31, 2013 1 Overview High priority areas for Sentinel sustainability Overview of Reagan-Udall
Public Consultation on Guideline on Authorization of Virtual Banks FTAHK response, March 2018
Public Consultation on Guideline on Authorization of Virtual Banks FTAHK response, March 2018 Contents Virtual Banking public consultation: FTAHK response FOREWORD 4 FEEDBACK AND GENERAL COMMENTS 5 CONCLUDING
Program Plan For the Energy Efficiency and Renewable Energy Technology Account Under New York s Clean Air Interstate Rules (CAIR)
Program Plan For the Energy Efficiency and Renewable Energy Technology Account Under New York s Clean Air Interstate Rules (CAIR) New York Battery and Energy Storage Technology Consortium Originally prepared
Take a Course of Action.
Take a Course of Action. When you choose RAPS Online University, you ll be on track to expand your regulatory knowledge and advance your career. Our comprehensive learning provides an immersive experience
Bristol Myers Squibb Holdings Pharma., Ltd.
Bristol Myers Squibb Holdings Pharma., Ltd. Department of Health and Human Services Public Health Service Food and Drug Administration 466 Fernandez Juncos Avenue Puerta De Tierra San Juan, Puerto Rico
FDA Reauthorization Act of 2017 (FDARA)
FDA Reauthorization Act of 2017 (FDARA) April 4, 2018 PRESENTED BY: Jessica Ringel Counsel FDA & Life Sciences Practice Group King & Spalding LLP (202) 626-9259 jringel@kslaw.com FDA Reauthorization Act
Name Position Telephone First contact
Report to the Minister of Statistics and Land Information: Proposal to Transfer the Open Government Information and Data Programme from Land Information New Zealand to Statistics New Zealand Date: 16 February
The Getting it Right Charter. Dan Scorer Head of Policy, Research & Public Affairs
The Getting it Right Charter Dan Scorer Head of Policy, Research & Public Affairs Background to the Charter 2010: Getting it Right Addressing the inequalities identified in Treat me right and Death by
Establishment of the FDA Office of Patient Affairs
Establishment of the FDA Office of Patient Affairs Policy Proposal: With the advent of new and innovative patient engagement programs within the Food and Drug Administration (FDA), a growing need for greater
Myanmar Country Partnership Framework (CPF) Background Material
Myanmar Country Partnership Framework (CPF) Background Material June 2014 The World Bank Group What is the World Bank Group? The World Bank is a vital source of financial and technical assistance to developing
Faster, More Efficient Innovation through Better Evidence on Real-World Safety and Effectiveness
Faster, More Efficient Innovation through Better Evidence on Real-World Safety and Effectiveness April 28, 2015 l The Brookings Institution Authors Mark B. McClellan, Senior Fellow and Director of the
Food Aid Safety and Quality Management Scheme
Food Aid Safety and Quality Management Scheme With a Look at FDA s Preventive Controls for Human Food Rule Ruffo Perez DCHA/FFP Senior Food Technology Advisor U.S. Agency for International Development
AWARDING FIXED OBLIGATION GRANTS TO NON-GOVERNMENTAL ORGANIZATIONS
AWARDING FIXED OBLIGATION GRANTS TO NON-GOVERNMENTAL ORGANIZATIONS An Additional Help Document For ADS Chapter 303 New Reference: 11/08/2010 Responsible Office: M/OAA File Name: 303saj_110810 I. PURPOSE
SHOULD I APPLY FOR AN ARC DECRA? GUIDELINES
SHOULD I APPLY FOR AN ARC DECRA? GUIDELINES Compiled by Gary Luck and Kate Organ, Research Office, CSU Synopsis ARC Discovery Early Career Researcher Awards (DECRA) fund projects that advance theory or
Washington County Public Health
Washington County Public Health Strategic Plan 2012-2016 Message from the Division Manager I am pleased to present the Washington County Public Health Division s strategic plan for fiscal years 2012 to
NUMBER: / /2009
Research Compliance ISSUED: 11/2002 REV. D: 11/2009 REV. A: REV. B: REV. C: 10/2005 7/2007 7/2008 11/2006 REV. E: 8/2016 PAGE 1 OF 5 IACUC 2.1 IACUC Members Initial Training All new IACUC members receive
MILITARY JUSTICE REVIEW GROUP
MILITARY JUSTICE REVIEW GROUP Presented to the Judicial Proceedings Panel Subcommittee October 22, 2015 Establishment of the MJRG Background A time of challenges Legislation approved 2013-2014 contained
Department of Defense
Department of Defense Environmental Management Systems Compliance Management Plan November 2009 Table of Contents EXECUTIVE SUMMARY... 3 I. INTRODUCTION... 4 II. DOD ENVIRONMENTAL PROGRAM OVERVIEW... 5
FACT (Foundation for the Accreditation of Cellular Therapy): Elizabeth Perry, MD
FACT (Foundation for the Accreditation of Cellular Therapy): An Inspector s View Elizabeth Perry, MD 11/7/08 Standards FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing,
November 7, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
1300 North 17 th Street Suite 1752 Arlington, Virginia 22209 Tel: 703.841.3200 Fax: 703.841.3392 www.medicalimaging.org November 7, 2011 Division of Dockets Management (HFA-305) Food and Drug Administration